First, go read the largely manufactured "study press release", relating to Saphris® (asenapine) longer-term treatement, v. a placebo. Yes, the dearth of longer-term, peer-reviewed human studies is a signal, but minor compared to what we’ve already discussed. This one is yet to be peer reviewed:
. . . .At the end of the double-blind phase, significantly fewer patients had relapsed with SAPHRIS than with placebo, 12 percent vs. 47 percent (P < 0.0001). In addition, the time to treatment discontinuation for any reason, a secondary efficacy assessment, was significantly longer with SAPHRIS than placebo (P < 0.001). These results were presented at a major European psychiatry congress in Istanbul, Turkey. . . .
Salmon will surely be along shortly, right here.